Saturday, April 20, 2024
HomeRecent ArticlesHI-Bio Raises $95 Mn Series B Funding to Advance Targeted Therapies

[Funding alert]HI-Bio Raises $95 Mn Series B Funding to Advance Targeted Therapies

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.

Read also – [Funding alert]Perplexity Raises $73.6M Series B Funding Round

Funding from the Series B will be used to advance clinical development of felzartamab, to evaluate the clinical properties of HIB210 in healthy volunteers and to advance a discovery-stage program targeting mast cell dysfunction toward IND-enabling studies. In conjunction with the financing, the company announced that Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global, has been appointed to the HI-Bio Board of Directors.

Read also – [Funding alert]Arbital Health Acquires Santa Barbara Actuaries and Closes  $10M Series A Funding

“These funds allow us to advance felzartamab, our clinically differentiated lead therapeutic candidate, through clinical readouts in multiple indications and preparation for registrational studies,” said Travis Murdoch, M.D., CEO of HI-Bio. “We are encouraged by promising clinical data to date for felzartamab and its anti-CD38 cell depletion approach, and we look forward to new data, including Phase 2 results from an investigator-initiated trial for antibody-mediated rejection in kidney transplant patients.”

Read also – [Funding alert]Nalu Medical Secures $65 Mn Equity Financing to Advance Treatment

“Immune-mediated diseases contribute to an immense disease burden which drives the need for novel targeted treatments to improve on existing therapies,” said Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global. “HI-Bio is generating compelling clinical data demonstrating the differentiated potential of felzartamab; we look forward to continued progress for felzartamab across multiple indications with high unmet need.”

Read also – [Funding alert] TN-based Seven Hills Capital secures an Inaugural fund

Funding from the Series B will be used to advance clinical development of felzartamab, to evaluate the clinical properties of HIB210 in healthy volunteers and to advance a discovery-stage program targeting mast cell dysfunction toward IND-enabling studies. In conjunction with the financing, the company announced that Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global, has been appointed to the HI-Bio Board of Directors.

Read also – MA-based Bruker Acquired Nion

About HI-Bio

Human Immunology Biosciences, Inc. (HI-Bio™) is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). HI-Bio is leading clinical immunology into its next chapter by targeting cellular drivers of disease.

Read also – NJ-based Cosette Pharmaceutical Acquired Vyleesi®

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular